The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Share News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps: Iofina, WYG, Akers Biosciences

Mon, 17th Sep 2012 07:34

WYG, a management and technical consultancy to the built and natural environment, says it will report a small operating profit in the first six months of the current year. The group is also poised to buy all three of WYG Ireland's subsidiaries in Northern Ireland, securing the jobs of around 90 employees in Belfast. WYG Ireland is going through a liquidation process. Iodine explorer and producer Iofina has reported like-for-like losses of £0.67m in the six months to the end of June. That compares to a loss of £0.43m in the same period of 2011. Revenues have also fallen from £5.95m to £4.9m. The group has however completed construction of its IO#1 extraction plant with construction also underway on a second facility. The group's shares have gained 170% in the last 12 months as iodine prices have strengthened. Akers Biosciences, which makes diagnostic and screening products, has raised $0.45m through an investment from US entrepreneur Thomas Knox. Knox has received 30m shares for his investment, which was made at 1.50 cents per Akers share, representing a small premium to the closing mid-market price of 1.2 cents (0.75p) on the last trading day before the placing announcement. In addition Knox has provided a $0.225m 3% promissory note in exchange for 10m preferred shares at 2.25 cents each. The preferred shares are convertible at any time into common shares, at the rate of five common shares for each preferred share, for an additional payment of $0.05 per converted Preferred Share. This conversion price is equivalent to $0.0145 per commons share and, if all the preferred shares were converted, would raise an additional $0.5m. The group has also reported revenues for the half year falling from $1.09m in the first half of 2011 to $0.787m this year. Losses have also widened from $0.838 to $1.02m. BS
More News
4 Nov 2014 16:15

UK AGM, EGM Calendar - Week Ahead

Read more
4 Nov 2014 08:21

UK MORNING BRIEFING: Legal & General, Imperial Tobacco Start Strongly

Read more
4 Nov 2014 06:13

UK AGM, EGM Calendar - Week Ahead

Read more
3 Nov 2014 16:09

UK AGM, EGM Calendar - Week Ahead

Read more
23 Oct 2014 12:30

Akers Biosciences Inks Joint Venture Deal With Hainin Savy In China

Read more
9 Sep 2014 16:02

MARKET COMMENT: London Ends Mixed Amid Boost From Production Data

Read more
9 Sep 2014 11:46

Akers Biosciences Signs USD864,000 Tri-Cholesterol "Check" Sales Deal

Read more
15 Aug 2014 07:39

UK MORNING BRIEFING: Miners Lead Broad-Based London Gains

Read more
15 Aug 2014 06:46

Akers Biosciences Appoints Co-Chairman

Read more
12 Aug 2014 10:42

Akers Biosciences Posts Wider Loss But Rise In Flagship Product Sales

Read more
28 Jul 2014 10:20

Akers Inks Feasibility Study Deal With Konica For Heart Attack Tests

Read more
17 Jul 2014 10:18

Akers Biosciences Breath Device Granted Patent

Read more
25 Jun 2014 13:28

REPEAT: Akers Biosciences Inks Distribution Agreement With Medline Industries

Read more
25 Jun 2014 12:40

UK MIDDAY BRIEFING: AbbVie Sets Out Case For Shire Acquisition

Read more
25 Jun 2014 12:10

Akers Biosciences secures US distribution for heparin test

Shares in Akers Biosciences were higher on news that it had secured a major distribution agreement in the US for its test to determine if patients will have a reaction to blood thinner heparin. The company's PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests with Medline Industries, which it said was

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.